Brokerages expect that Radius Health Inc (NASDAQ:RDUS) will report earnings per share (EPS) of ($0.83) for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Radius Health’s earnings, with estimates ranging from ($0.94) to ($0.64). Radius Health posted earnings per share of ($0.77) during the same quarter last year, which would indicate a negative year over year growth rate of 7.8%. The company is expected to report its next quarterly earnings results on Wednesday, August 5th.
On average, analysts expect that Radius Health will report full year earnings of ($2.79) per share for the current fiscal year, with EPS estimates ranging from ($3.39) to ($2.29). For the next fiscal year, analysts forecast that the firm will report earnings of ($1.39) per share, with EPS estimates ranging from ($1.62) to ($0.84). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Radius Health.
Radius Health (NASDAQ:RDUS) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.09). The business had revenue of $47.92 million during the quarter, compared to analysts’ expectations of $46.77 million.
Several equities analysts recently issued reports on RDUS shares. Stifel Nicolaus started coverage on Radius Health in a research note on Thursday, April 23rd. They set a “hold” rating and a $20.00 price objective on the stock. Zacks Investment Research cut Radius Health from a “buy” rating to a “hold” rating and set a $13.00 price objective on the stock. in a research note on Thursday, June 4th. BidaskClub raised Radius Health from a “sell” rating to a “hold” rating in a research report on Tuesday, June 23rd. Morgan Stanley lowered Radius Health from an “overweight” rating to an “equal weight” rating and set a $20.00 target price on the stock. in a research report on Wednesday, May 13th. Finally, JPMorgan Chase & Co. lowered their target price on Radius Health from $32.00 to $27.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Seven analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $26.25.
In related news, major shareholder Target N. V. Biotech acquired 50,000 shares of the business’s stock in a transaction that occurred on Thursday, April 30th. The shares were acquired at an average cost of $15.75 per share, with a total value of $787,500.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 2.92% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of RDUS. Norges Bank bought a new position in Radius Health in the 4th quarter worth approximately $7,677,000. Renaissance Technologies LLC increased its position in Radius Health by 311.6% in the 4th quarter. Renaissance Technologies LLC now owns 444,159 shares of the biopharmaceutical company’s stock worth $8,954,000 after buying an additional 336,259 shares during the period. Tang Capital Management LLC bought a new position in Radius Health in the 1st quarter worth approximately $3,900,000. Artisan Partners Limited Partnership increased its position in Radius Health by 17.6% in the 4th quarter. Artisan Partners Limited Partnership now owns 1,194,776 shares of the biopharmaceutical company’s stock worth $24,087,000 after buying an additional 178,756 shares during the period. Finally, Jacobs Levy Equity Management Inc. grew its holdings in shares of Radius Health by 572.2% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 196,807 shares of the biopharmaceutical company’s stock worth $3,968,000 after purchasing an additional 167,527 shares in the last quarter.
Shares of Radius Health stock traded up $0.23 on Thursday, hitting $14.40. 6,984 shares of the company’s stock traded hands, compared to its average volume of 453,900. The stock has a market cap of $664.31 million, a P/E ratio of -5.17 and a beta of 1.19. The firm’s 50-day moving average is $13.38 and its 200 day moving average is $16.23. Radius Health has a 52-week low of $10.32 and a 52-week high of $29.97.
About Radius Health
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
Featured Story: Determine Your Level of Risk Tolerance
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.